Nanjing Reju Therapeutics

Nanjing Reju Therapeutics is a biotechnology company dedicated to the discovery and development of therapies for aging and age-related diseases. Headquartered in Nanjing, China, the company was established as a strategic venture between Fosun Pharma and Insilico Medicine, leveraging advanced artificial intelligence to identify novel longevity targets. Reju's research focuses on cellular rejuvenation and the restoration of tissue function, with a primary pipeline targeting skin aging, sarcopenia, and fibrotic conditions. By integrating AI-driven drug discovery with deep expertise in aging biology, the company aims to develop first-in-class small molecule treatments that extend human healthspan. Reju is positioned at the intersection of longevity science and digital drug discovery, seeking to transform how age-related decline is treated clinically. The company benefits from the combined strengths of Insilico's computational platform and Fosun's extensive clinical and commercial infrastructure.